fda safety communication semaglutide vision loss naion 2025 GLP-1 Medications and NAION: What Patients Should Know About Sudden Wegovy FDA Approval: CV Risk

Description

But human observational evidence is increasingly reassuring on major malformations when confounding is handled carefullyfor example, large datasets show no substantial increased risk of major congenital malformations with early exposure, and a European teratology cohort reported no increase in major birth defects vs diabetes/high-BMI comparators

Nausea on Ozempic or Wegovy

D-Panthenol (Vitamin B5)

Electrolysis Like laser, electrolysis involves a significant investment upfront 10-15 professional sessions, up to 18 months, and thousands of dollars to see full results, but the results are permanent

Conclusion The current evidence suggests a possible association between use of GLP-1RA and an increased risk of depression, but overall risk seems to be dominated by population characteristics, drug class, and how mood outcomes are assessed